<DOC>
	<DOCNO>NCT02156297</DOCNO>
	<brief_summary>It prospective , non-interventional , open-label study , order observe safety response FLT3-ITD mutation positive AML patient receive sorafenib induction , consolidation , salvage , maintenance alleviative treatment . The duration study June 2014 May 2019 , recruitment duration June 2014 May 2017 . The inclusion criterion : 1 . Definitely diagnose AML 2 . FLT3-ITD mutation confirm 3 . Accepting prescription sorafenib</brief_summary>
	<brief_title>Sorafenib Treat FLT3-ITD AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Definitely diagnose AML FLT3ITD mutation confirm Accepting prescription sorafenib Can take drug orally Can follow doctor ' advice Other reason investigator consider contraindication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>